Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 PCSK9 inhibitors

Literature DB >> 27789927

PCSK9 inhibitors - mechanisms of action.

Michael M Page¹, Gerald F Watts².

Abstract

Entities: Gene

Keywords: LDL cholesterol; familial hypercholesterolaemia; proprotein convertase subtilisin/kexin type 9

Year: 2016 PMID： 27789927 PMCID： PMC5079795 DOI： 10.18773/austprescr.2016.060

Source DB: PubMed Journal: Aust Prescr ISSN： 0312-8008

× No keyword cloud information.

14 in total

1. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

Authors: Jonathan C Cohen; Eric Boerwinkle; Thomas H Mosley; Helen H Hobbs
Journal: N Engl J Med Date: 2006-03-23 Impact factor: 91.245

Review 2. Lipoprotein(a) as a therapeutic target in cardiovascular disease.

Authors: Marlys Koschinsky; Michael Boffa
Journal: Expert Opin Ther Targets Date: 2014-05-22 Impact factor: 6.902

3. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.

Authors: Evan A Stein; Narimon Honarpour; Scott M Wasserman; Feng Xu; Rob Scott; Frederick J Raal
Journal: Circulation Date: 2013-09-06 Impact factor: 29.690

4. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.

Authors: Frederick J Raal; Robert P Giugliano; Marc S Sabatine; Michael J Koren; Gisle Langslet; Harold Bays; Dirk Blom; Mats Eriksson; Ricardo Dent; Scott M Wasserman; Fannie Huang; Allen Xue; Moetaz Albizem; Rob Scott; Evan A Stein
Journal: J Am Coll Cardiol Date: 2014-02-05 Impact factor: 24.094

Review 5. A receptor-mediated pathway for cholesterol homeostasis.

Authors: M S Brown; J L Goldstein
Journal: Science Date: 1986-04-04 Impact factor: 47.728

6. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor.

Authors: Rocco Romagnuolo; Corey A Scipione; Michael B Boffa; Santica M Marcovina; Nabil G Seidah; Marlys L Koschinsky
Journal: J Biol Chem Date: 2015-03-16 Impact factor: 5.157

7. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors: Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal: Nat Genet Date: 2003-06 Impact factor: 38.330

8. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.

Authors: Hagai Tavori; Daping Fan; John L Blakemore; Patricia G Yancey; Lei Ding; Macrae F Linton; Sergio Fazio
Journal: Circulation Date: 2013-05-20 Impact factor: 29.690

9. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor.

Authors: Hua Sun; Amin Samarghandi; Ningyan Zhang; Zemin Yao; Momiao Xiong; Ba-Bie Teng
Journal: Arterioscler Thromb Vasc Biol Date: 2012-05-10 Impact factor: 8.311

Review 10. Sorting an LDL receptor with bound PCSK9 to intracellular degradation.

Authors: Trond P Leren
Journal: Atherosclerosis Date: 2014-09-02 Impact factor: 5.162

18 in total

Review 1. Evolocumab.

Authors:
Journal: Aust Prescr Date: 2016-10-01

Review 2. Primary and Novel Lipid-Lowering Therapies to Reduce Risk in Patients With Peripheral Arterial Disease.

Authors: Alicia Chionchio; Andrew Galmer; Benjamin Hirsh
Journal: Curr Treat Options Cardiovasc Med Date: 2019-12-17

Review 3. Dyslipidemia in patients with chronic kidney disease.

Authors: Matthew R Hager; Archana D Narla; Lisa R Tannock
Journal: Rev Endocr Metab Disord Date: 2017-03 Impact factor: 6.514

Review 4. Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events.

Authors: Sara Lee; Christopher P Cannon
Journal: Curr Cardiol Rep Date: 2018-05-25 Impact factor: 2.931

Review 5. Usefulness of alirocumab and evolocumab for the treatment of patients with diabetic dyslipidemia.

Authors: Jun Zhang; Kristen M Tecson; Natalia A Rocha; Peter A McCullough
Journal: Proc (Bayl Univ Med Cent) Date: 2018-04-11

Review 6. Proprotein convertase inhibition: Paralyzing the cell's master switches.

Authors: Andres J Klein-Szanto; Daniel E Bassi
Journal: Biochem Pharmacol Date: 2017-04-27 Impact factor: 5.858

Review 7. Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition.

Authors: Huimin Sun; Wen Meng; Jie Zhu; Lu Wang
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2022-03-21 Impact factor: 3.000